Preview

Rational Pharmacotherapy in Cardiology

Advanced search

POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE

https://doi.org/10.20996/1819-6446-2013-9-1-31-34

Full Text:

Abstract

Aim. To evaluate the functional activity of platelets by the optical standard aggregatometry and induced flow cytofluorometry during antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA).

Material and methods. The evaluation of platelet function in 30 patients with ischemic heart disease treated with dual antiplatelet therapy (ASA and clopidogrel) was performed by two methods: the standard photometric method with the assessment of degree of light transmission at the maximum point and by the original method of induced flow cytofluorometry with the platelet activity evaluation by changing of glycoprotein (GP) IIb/IIIa receptor level and the expression of P-selectin before and after ADP induction.

Results. Increase in platelet functional activity was detected in patients with ASA monotherapy at initial evaluation by both induced flow cytofluorometry and standard photometric method. After one month dual antiplatelet therapy platelet function significantly decreased according to standard photometric method (from 61.4Ѓ}3.6 to 45.9Ѓ}3.7; p<0.05; the induction of 2.5 mM ADP), as well as according to flow cytofluorometry with changing of GP IIb/IIIa receptor level (from 12.2Ѓ}0.8% to 5.2Ѓ}0.8%; p<0.05) and the expression of P-selectin (from 70.5Ѓ}5.9% to 57.4Ѓ}5.9%; p<0.05).

Conclusion. The combined use of laboratory methods to assess platelet function (traditional and high-tech) provides cardiologist with additional tool for assessing the effectiveness of antiplatelet therapy in patients with ischemic heart disease.

About the Authors

O. V. Sirotkina
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg; Petersburg Nuclear Physics Institute named after B.P. Konstantinov, Gatchina, Leningrad region
Russian Federation


A. B. Laskovets
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg
Russian Federation


A. S. Lipunova
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg
Russian Federation


L. B. Gaykovaya
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg
Russian Federation


S. A. Boldueva
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg
Russian Federation


T. V. Vavilova
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg
Russian Federation


References

1. Trip M.D., Cats M., van Cappelle F.J., Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322(22): 1549–1554 2. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998; 19(Suppl.C): C39– C43

2. Ruksin V.V. Thrombosis in cardiology practice. Moscow: Binom, 1998. Russian (Руксин В.В. Тромбозы в кардиологической практике. М.: Бином, 1998).

3. Ardissino D., Mannucci P.M., Merlini P.A. et al. Protrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46–51

4. Folsom A.R. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86: 366–373

5. Bokarev I.N., editor. Antiplatelet therapy in clinical practice. Guidelines. Moscow: RKI Sovero press; 2008. Russian (Бокарев И.Н., редактор. Противотромбоцитарная терапия в клинической практике. Методические рекомендации. М.: РКИ Соверо пресс; 2008).

6. Meadows T.A., Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261–1275

7. Cattaneo M. New P2Y12 blockers. J Thromb Haemost 2009; 7(Suppl): 262–265

8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapyfor prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86

9. Oestreich J.H., Smyth S., Campbell Ch. Platelet function analysis: at the edge of meaning. Thromb Haemost 2009; 101(2): 217–219

10. Guyatt G.H., Akl E.A., Crowther M. et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 7S–47S

11. Hayward C.P.M. Advances in understanding “high on-treatment platelet reactivity”. Thromb Haemost 2009; 102: 799–800

12. Born G. V. Quantitative investigations into aggregation of blood platelets. J Physiol 1962; 162: 67– 68

13. Born G.V. Aggregation of platelet by adenosine diphosphate and its reversal. Nature 1964; 194: 927– 929

14. O’Brien D.K., Heywood J.B., Heady J.A. The quantitation of platelet aggregation induced by four compounds: A study relation to myocardial infarction. Thromb Haemorrh 1966; 16: 725–767

15. Sirotkina O.V., Bogan'kova N.A., Laskovets A.B. et al. Immunological methods in the evaluation of platelet function in patients with cardiovascular diseases. Meditsinskaya Immunologiya 2010; 12(3): 213– 218. Russian (Сироткина О.В., Боганькова Н.А., Ласковец А.Б. и соавт. Иммунологические методы в оценке функциональной активности тромбоцитов у больных с сердечно-сосудистыми заболеваниями. Медицинская Иммунология 2010; 12(3): 213–218).

16. Sirotkina O.V., Gaykovaya L.B., Vavilova T.V., et al. A method for evaluating the effectiveness of antiplatelet drugs that affect the metabolism of arachidonic acid by inhibiting cyclooxygenase-1 both individually and jointly with ADP receptor antagonist P2Y12 platelet membranes on, the state of blood platelets patient taking antiplatelet drugs of this group. Patent № 2442167. Russian (Сироткина О.В., Гайковая Л.Б., Вавилова Т.В., и др. ≪Способ оценки эффективности действия антиагрегантных препаратов, влияющих на метаболизм арахидоновой кислоты путем ингибирования циклооксигеназы-1 как в отдельности, так и совместно с антагонистом рецептора АДФ P2Y12 на тромбоцитарных мембранах, на состояние тромбоцитов крови пациента, принимающего антиагрегантные препараты указанной группы≫. Патент на изобретение № 2442167).

17. Sirotkina O.V., Vavilova T.V. Algorithms for molecular genetic testing to determine individual sensitivity to antiplatelet drugs – a step toward personalized medicine. Aterotromboz 2012; (1): 49–55. Russian (Сироткина О.В., Вавилова Т.В. Алгоритм лабораторного молекулярно-генетического исследования для определения индивидуальной чувствительности к антиагрегантным препаратам — шаг навстречу персонализированной медицине. Атеротромбоз 2012; (1): 49–55).

18. Marcucci R., Gori A.M., Paniccia R. et al. High on-treatment platelet reactivity by more than one agonist predict 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients received coronary stenting. Thromb Haemost 2010; 104(2): 279–286

19. Vlachojannis G.J., Dimitropoulos G., Alexopoulos D. Clopidogrel resistance: current aspects and future directions. Hellenic J Cardiol 2011; 52: 236–245

20. da Silva F.B., de Almeida Junior G.L.G., Neno A. Resistance to clopidogrel: prevalence and associate variables. Arq Bras Cardiol 2012; 99(6): 1135–1141


For citation:


Sirotkina O.V., Laskovets A.B., Lipunova A.S., Gaykovaya L.B., Boldueva S.A., Vavilova T.V. POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2013;9(1):31-34. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-1-31-34

Views: 497


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)